in those with a high frequency of hypoglycemia) may increase oxidative stress and promote innate or adaptive immune dysfunction, leading to an increased chance of infection ( Despite a large body of scientific research, GLP-1RA demonstrated a positive effect with a 14% reduction in major cardiovascular events (MACE) [HR=0.86, 95%CI(0.79-0.94), p =0.006] and no significant heterogeneity was observed between subgroups of individuals with or without cardiovascular disease ( p =0.127)
This often occurs alongside other gastrointestinal issues such as bloating, diarrhea, and vomiting
Medical professionals must educate patients about proper injection techniques, timing, and storage requirements
Quatraro, A., Roca, P., Donzella, C., Acampora, R., Marfella, R., and Giugliano, D
Baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimers disease
Int J Mol Sci (2015) 16(9):20195211